knowledge -WSS

knowledge

author：fashion 2025-09-30 12:10:41 - browse：16

Medicare and money photo illustration. — Adobe

Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier.

CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

“I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Three issues to watch in global health in 2024

WSS

New England Journal of Medicine addresses racist history, slavery

New Medicare drug pricing powers could soon be upended in court

Report captures long Covid’s disabling effects and policy challenges

HHS names first

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Heart disease and mental health: A look at cardiac psychology

hotspot

knowledge

knowledge

Walensky prepares to leave CDC — and Congress — behind

Readers discuss the intersection of pregnancy and addiction

Peter Hotez and the public health issue of online harassment

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

In age of alternative facts, a scholarly course on calling out crap

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Walensky prepares to leave CDC — and Congress — behind

5 takeaways from STAT's examination of Zynex Medical

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Wikipedia

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

The SUPPORT Act is critical to fighting the opioid crisis

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

New Medicare drug pricing powers could soon be upended in court

As JPM 2024 winds down, some health tech firms project optimism

As JPM 2024 winds down, some health tech firms project optimism

Wikipedia

focus

entertainment

leisure time